Gilead Sciences (GILD) : Jolley Asset Management added new position in Gilead Sciences during the most recent quarter end. The investment management firm now holds 1,014 shares of Gilead Sciences which is valued at $103,357 , the company said in a statement filed on Apr 21, 2016 with the SEC.Gilead Sciences makes up approximately 0.09% of Jolley Asset Management’s portfolio.
Gilead Sciences closed down -0.61 points or -0.60% at $100.72 with 85,85,754 shares getting traded on Wednesday. Post opening the session at $101.3, the shares hit an intraday low of $100.15 and an intraday high of $101.78 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Seaward Management Limited Partnership reduced its stake in GILD by selling 103,117 shares or 24.62% in the most recent quarter. The Hedge Fund company now holds 315,727 shares of GILD which is valued at $32,182,053. Gilead Sciences makes up approx 1.72% of Seaward Management Limited Partnership’s portfolio.Windward Capital Management Co Ca boosted its stake in GILD in the latest quarter, The investment management firm added 1,073 additional shares and now holds a total of 40,242 shares of Gilead Sciences which is valued at $4,101,867. Gilead Sciences makes up approx 0.79% of Windward Capital Management Co Ca’s portfolio.Profit Investment Management reduced its stake in GILD by selling 22,545 shares or 31.11% in the most recent quarter. The Hedge Fund company now holds 49,927 shares of GILD which is valued at $5,089,059. Gilead Sciences makes up approx 2.13% of Profit Investment Management’s portfolio.Neville Rodie Shaw Inc reduced its stake in GILD by selling 33,844 shares or 23.11% in the most recent quarter. The Hedge Fund company now holds 112,617 shares of GILD which is valued at $11,069,125. Gilead Sciences makes up approx 1.33% of Neville Rodie Shaw Inc’s portfolio.Howland Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 1,334 additional shares and now holds a total of 259,254 shares of Gilead Sciences which is valued at $25,482,076. Gilead Sciences makes up approx 2.56% of Howland Capital Management’s portfolio.
On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.